OBJECTIVE: There are increasing calls for a precise, automated system to enable tight glycemic control and to avoid hypoglycemia in an intensive care unit setting. OptiScan Biomedical has developed a glucose monitor based on mid-infrared spectroscopy that withdraws blood samples (120 µl) and measures plasma glucose. The goal of this study was to validate the performance of the OptiScan Model 5000 over a wide range of glycemic levels in patients. RESEARCH DESIGN AND METHODS: Sixty people with type 1 (n = 18) or type 2 (n = 42) diabetes who were otherwise healthy were connected to OptiScanners. Their blood glucose concentrations were kept in a euglycemic, hypoglycemic (<75 mg/dl), and hyperglycemic (>180 mg/dl) range by intravenous administrations of insulin and glucose. OptiScanner venous blood samples were automatically withdrawn every 15 minutes. Reference measurements were done using the YSI 2300 glucose analyzer. RESULTS: The aggregate data points (1155 paired readings) were within International Organization for Standardization standards, with 98.6% of the glucose values within ±20% above 75 mg/dl and ±15 mg/dl below this value. A Clarke error grid analysis showed a total of 1139 points (98.6%) in zone A. Points outside of A exceeded the A zone boundary by an average of 4.3%. The r(2) was 0.99. The total coefficient for variance was 6.4%. CONCLUSIONS: These results show that the OptiScanner is highly accurate in healthy patients with diabetes across a wide range of glucose values. Mid-infrared spectroscopy may become the method of choice for highly accurate, high frequency, automated glucose measurements and may thus enable better glycemic control in critically ill patients.
OBJECTIVE: There are increasing calls for a precise, automated system to enable tight glycemic control and to avoid hypoglycemia in an intensive care unit setting. OptiScan Biomedical has developed a glucose monitor based on mid-infrared spectroscopy that withdraws blood samples (120 µl) and measures plasma glucose. The goal of this study was to validate the performance of the OptiScan Model 5000 over a wide range of glycemic levels in patients. RESEARCH DESIGN AND METHODS: Sixty people with type 1 (n = 18) or type 2 (n = 42) diabetes who were otherwise healthy were connected to OptiScanners. Their blood glucose concentrations were kept in a euglycemic, hypoglycemic (<75 mg/dl), and hyperglycemic (>180 mg/dl) range by intravenous administrations of insulin and glucose. OptiScanner venous blood samples were automatically withdrawn every 15 minutes. Reference measurements were done using the YSI 2300 glucose analyzer. RESULTS: The aggregate data points (1155 paired readings) were within International Organization for Standardization standards, with 98.6% of the glucose values within ±20% above 75 mg/dl and ±15 mg/dl below this value. A Clarke error grid analysis showed a total of 1139 points (98.6%) in zone A. Points outside of A exceeded the A zone boundary by an average of 4.3%. The r(2) was 0.99. The total coefficient for variance was 6.4%. CONCLUSIONS: These results show that the OptiScanner is highly accurate in healthy patients with diabetes across a wide range of glucose values. Mid-infrared spectroscopy may become the method of choice for highly accurate, high frequency, automated glucose measurements and may thus enable better glycemic control in critically illpatients.
Authors: Johannes Plank; Jan Blaha; Jeremy Cordingley; Malgorzata E Wilinska; Ludovic J Chassin; Cliff Morgan; Stephen Squire; Martin Haluzik; Jaromir Kremen; Stepan Svacina; Wolfgang Toller; Andreas Plasnik; Martin Ellmerer; Roman Hovorka; Thomas R Pieber Journal: Diabetes Care Date: 2006-08 Impact factor: 19.112
Authors: Brad S Karon; Laurie Griesmann; Renee Scott; Sandra C Bryant; Jeffrey A Dubois; Terry L Shirey; Steven Presti; Paula J Santrach Journal: Diabetes Technol Ther Date: 2008-04 Impact factor: 6.118
Authors: Simon Finfer; Dean R Chittock; Steve Yu-Shuo Su; Deborah Blair; Denise Foster; Vinay Dhingra; Rinaldo Bellomo; Deborah Cook; Peter Dodek; William R Henderson; Paul C Hébert; Stephane Heritier; Daren K Heyland; Colin McArthur; Ellen McDonald; Imogen Mitchell; John A Myburgh; Robyn Norton; Julie Potter; Bruce G Robinson; Juan J Ronco Journal: N Engl J Med Date: 2009-03-24 Impact factor: 91.245
Authors: X W Wong; I Singh-Levett; L J Hollingsworth; G M Shaw; C E Hann; T Lotz; J Lin; O S W Wong; J G Chase Journal: Diabetes Technol Ther Date: 2006-04 Impact factor: 6.118
Authors: Dirk Vlasselaers; Ilse Milants; Lars Desmet; Pieter J Wouters; Ilse Vanhorebeek; Ingeborg van den Heuvel; Dieter Mesotten; Michael P Casaer; Geert Meyfroidt; Catherine Ingels; Jan Muller; Sophie Van Cromphaut; Miet Schetz; Greet Van den Berghe Journal: Lancet Date: 2009-01-26 Impact factor: 79.321
Authors: Elizabeth A Mann; Heather F Pidcoke; Jose Salinas; John B Holcomb; Steven E Wolf; Charles E Wade Journal: J Burn Care Res Date: 2008 Sep-Oct Impact factor: 1.845
Authors: Thomas M Scalea; Grant V Bochicchio; Kelly M Bochicchio; Steven B Johnson; Manjari Joshi; Anne Pyle Journal: Ann Surg Date: 2007-10 Impact factor: 12.969
Authors: Grant V Bochicchio; Manjari Joshi; Kelly M Bochicchio; Anne Pyle; Steven B Johnson; Walter Meyer; Kim Lumpkins; Thomas M Scalea Journal: J Trauma Date: 2007-12
Authors: Felix Aberer; Verena Theiler-Schwetz; Haris Ziko; Bettina Hausegger; Iris Wiederstein-Grasser; Daniel A Hochfellner; Philipp Eller; Georg Tomberger; Martin Ellmerer; Julia K Mader; Vladimir Bubalo Journal: Sci Rep Date: 2020-04-20 Impact factor: 4.379
Authors: Roosmarijn Tm van Hooijdonk; Tineke Winters; Johan C Fischer; Edmée C van Dongen-Lases; James S Krinsley; Jean-Charles Preiser; Marcus J Schultz Journal: Ann Intensive Care Date: 2014-03-06 Impact factor: 6.925